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Smooth muscle cell 
Biodegradable 
Stent 
a b s t r a c t 
Zinc is an essential trace element having various structural, catalytic and regulatory interactions with an estimated 
3000 proteins. Zinc has drawn recent attention for its use, both as pure metal and alloyed, in arterial stents 
due to its biodegradability, biocompatibility, and low corrosion rates. Previous studies have demonstrated that 
zinc metal implants prevent the development of neointimal hyperplasia, which is a common cause of restenosis 
following coronary intervention. This suppression appears to be smooth muscle cell-specific, as reendothelization 
of the neointima is not inhibited. To better understand the basis of zinc’s differential effects on rat aortic smooth 
muscle (RASMC) versus endothelial (RAENDO) cells, we conducted a transcriptomic analysis of both cell types 
following one-week continuous treatment with 5 μM or 50 μM zinc. This analysis indicated that genes whose 
protein products regulate mitochondrial functions, including oxidative phosphorylation and fusion/fission, are 
differentially affected by zinc in the two cell types. To better understand this, we performed Seahorse metabolic 
flux assays and quantitative imaging of mitochondrial networks in both cell types. Zinc treatment differently 
affected energy metabolism and mitochondrial structure/function in the two cell types. For example, both basal 
and maximal oxygen consumption rates were increased by zinc in RASMC but not in RAENDO. Zinc treatment 
increased apparent mitochondrial fusion in RASMC cells but increased mitochondrial fission in RAENDO cells. 
These results provide some insight into the mechanisms by which zinc treatment differently affects the two 
cell types and this information is important for understanding the role of zinc treatment in vascular cells and 
improving its use in biodegradable metal implants. 
Introduction 
Percutaneous coronary intervention is a common practice to estab- 
lish revascularization during stenotic arterial disease. This procedure is 
typically accompanied by the surgical placement of a stent to prevent 
post-angioplasty restenosis [1] . In the past, such stents remained in the 
artery for the lifetime of the patient resulting in the development of 
adverse side effects including smooth muscle neointimal hyperprolifera- 
tion, thrombogenesis and destructive inflammation [ 2 , 3 ]. The advent of 
biodegradable/ bioabsorbable metal stents, which persist long enough 
to allow the return of normal vascular function, has been useful in pre- 
venting the development of long-term side effects. 
Several metals have been evaluated for use in biodegrad- 
able/bioabsorbable stents including iron and magnesium, both as pure 
metal and alloyed. However, assessment of these metals has revealed 
several limitations; iron has a low corrosion rate- leading to similar ad- 
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verse effects as found in permanent stents, and magnesium has poor 
mechanical strength and increased corrosion rates leading to local al- 
kalization and early loss of mechanical integrity [4–11] . More recently, 
there has been significant progress in the use of zinc-based alloys for 
bioabsorbable stents. Zinc is an essential trace metal in the body which 
interacts with an estimated 3000 proteins; participating in several criti- 
cal cellular functions including nucleic acid/protein metabolism as well 
as cell growth and division [12–14] . Recent studies have observed a ben- 
eficial suppressive effect of neointimal hyperplasia in the presence of 
zinc metal implants. In a model of stent implantation, a zinc metal wire 
was surgically placed in the abdominal aorta of Sprague-Dawley rats for 
6 months. Here, confluent endothelization along the luminal surface of 
the zinc metal wire implant was observed in addition to a decreasing 
gradient of smooth muscle cells close to the implant surface [15] . Con- 
sistent with this, a similar gradient was observed with pure zinc stent 
implants in rabbit abdominal aorta [16] . These results suggest that zinc 
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corrosion products released from metal implants suppress smooth mus- 
cle cell hyperproliferation but do not affect endothelization or smooth 
muscle cells in the medial layer of the aorta [ 15 , 17 ]. To examine this 
effect further, an ex vivo arterial culture study washed tissue slices pre- 
pared from the thoracic aorta of rats with 0.5–1.5 mM Zn-acetate to 
simulate zinc corrosion products. Suppression of caspase-8 and -9 ac- 
tivity was observed at high concentrations, as well as a dose-dependent 
activation of caspase-3 activity [17] . These results are consistent with 
studies that have demonstrated decreased cell viability in response to 
zinc exposure [ 6 , 10 ]. While it may be accepted that zinc acts as a potent 
inhibitor of caspase-3,-8 and -9 activity at concentrations above 100 μM, 
most of such studies have been performed in isolated enzyme systems 
which lack many of the critical compartments, organelles and compet- 
ing proteins which may render such effects negligible in vivo [17–20] . 
Collectively, these results indicate a complex relationship between zinc 
exposure and caspase activation in intact cells which likely translates to 
other zinc effects evaluated in isolated mitochondria. 
We describe herein the effects of one-week continuous zinc expo- 
sure in vascular cells to model their response to zinc-based stents in 
vivo . Previous studies have evaluated the cellular response of rat aortic 
smooth muscle and endothelial cells for up to 24 h [ 6 , 10 ]. While this 
approach may highlight cellular signaling pathways targeted by exoge- 
nous zinc, it does not model the more relevant physiological adaptation 
of cells exposed to a slowly degrading metal implant in vivo . A typical 
zinc-based stent is approximately 50 mg of pure metal [22–24] . If we as- 
sume the stent degrades completely within 18 months (ideal bioabsorp- 
tion: 12–24 months), this results in approximately 90 μg zinc released 
per day on average [ 22 , 25 ]. High velocity blood flow in coronary arter- 
ies ( ∼250 ml/min) likely facilitates rapid clearance of zinc degradation 
products from the lumen [26] , but not those released from the surface in 
contact with the neointima surrounding the stent [17] . We do not have 
data on the concentrations of zinc that develop in the neointima, and in- 
deed a concentration gradient will be present from the stent to surround- 
ing tissue cells. We chose to treat cells with a relatively low concentra- 
tion of zinc (5 μM) and a ten-fold higher concentration (50 μM). We 
predict that, in vivo , cells in the neointima of a stent-containing artery 
would encounter zinc concentrations within this range. 
RNA-seq analyses of rat aortic endothelial and smooth muscle cells in 
these experiments revealed significant effects of zinc on gene expression 
in both cell types, with a primarily mitochondrial response at low con- 
centration (5 μM) and upregulation of proteins required for regulation of 
metal homeostasis at higher concentrations (50 μM). Evaluation of cel- 
lular respiration and mitochondrial network characteristics of both cell 
types following zinc treatment revealed differential effects on oxidative 
phosphorylation and mitochondrial dynamics. 
Experimental section 
Zn 2 + solution 
ZnSO 4 -heptahydrate (Sigma, Z-0251) was dissolved in Milli-Q water 
from a GenPure UV/UF xCAD plus Ultrapure water purification system 
(Thermo Scientific, 50136151) and subsequently autoclaved. 100 mM 
stock solutions were stored at -20 °C and serial dilutions were made in 
sterile-filtered (0.20 μM polyethersulfone) Milli-Q water prior to each 
experiment. 
Cell culture 
Primary rat aortic endothelial cells (Cell Biologics, RN-6052) and rat 
aortic smooth muscle cells (Lonza, R-ASM-580) were cultured in phys- 
iologically representative media (Plasmax) formulated as described in 
[21] . Plasmax media was supplemented with 10% fetal bovine serum 
(Sigma, F1051), 1% penicillin/streptomycin (Sigma, P4333), 6.5 mM 
L-glutamine and 1 mM sodium pyruvate to ensure adequate growth of 
primary cells. Cells were incubated in physiologically relevant oxygen 
levels within a 5% CO 2 / 5% O 2 humidified incubator (Keeley and Mann 
2019). Sub-culture was performed with 0.25% tryspin/EDTA solution 
(Sigma, T4049). Media was refreshed every 24 h. Cells were cultured for 
7 days at a final ZnSO 4 concentration of 0 μM (Control), 5 μM, 50 μM. 
RNA isolation and sequencing 
Total cellular RNA was extracted isolated using the RNEasy Plus Mini 
Kit (Qiagen, 74131) according to the manufacturer’s protocol. RNA con- 
centration and purity were evaluated as A260/280 ratio using a Thermo 
Fisher Scientific Nanodrop spectrometer. RNA samples were then snap 
frozen in liquid nitrogen and stored at -80 °C until being sent to Novo- 
gene (Sacramento, CA) for sequencing and analysis. Pair-ends at 150 bp 
(PE150) high throughput Illumina sequencing was performed at read- 
depth of 40 million reads. The HISAT2 algorithm [27] was used to align 
reads to the reference genome ( Rattus Norvegicus ). Gene expression lev- 
els were estimated by calculating FPKM (fragments per kilobase of tran- 
script per million mapped sequence reads), which were further adjusted 
using trimmed mean of M values (TMM) [28] before differential expres- 
sion analysis was performed using the EdgeR R package [29] . 
Gene ontology (GO) term analysis 
GO term analysis was performed using the Database for Annotation, 
Visualization and Integrated Discovery (DAVID) v.6.8 with the default 
settings ( https://david.ncifcrf.gov ) [ 30 , 31 ]. The GO direct annotation 
level was used to obtain enriched GO terms. Gene lists of differentially 
expressed genes (DEG) provided by Novogene were reduced to genes 
with a Benjamini adjusted p -value < 0.005 in order to produce a concise 
list of GO terms which reflect the most strongly affected genes. 
Cellular respiration 
Cellular respiration parameters were measured using a Seahorse Ex- 
tracellular Flux Analyzer XF e 24 Mito Stress test (Agilent, Santa Clara, 
CA). Measurements were performed using Plasmax media without 
serum, sodium bicarbonate or penicillin/streptomycin supplementation. 
The Mito Stress Test was performed using 1 μM oligomycin A, 1 μM 
FCCP and 0.5 μM Rotenone/antimycin A, added according to standard 
protocol. At the end of the test, cells were trypsinized, isolated and 
counted in triplicate using a hemocytometer. Oxygen consumption rate 
(OCR) and extracellular acidification rate (ECAR) were normalized to 
total cells in all experiments. 
Fluorescence microscopy 
Cells were seeded on 35 mm Mattek cell culture imaging plates (L- 
lysine-coated) on Day 5 of zinc treatments. On Day 7, media was re- 
moved and replaced with media containing 10 nM tetramethyl rho- 
damine methyl ester (TMRM) (Biotium, 70017) and incubated for 
30 min. Images were obtained on a Zeiss Cell Observer SD spinning 
disk confocal microscope equipped with Teledyne Photometric Prime 
BSI and Yokogawa Sensor Cameras. Images were analyzed using Im- 
ageJ. 
Measurement of mitochondrial membrane potential 
TMRM fluorescence images were cropped into individual cells, while 
minimizing overlap of nearby cells. Cells containing multiple nuclei (ac- 
tively dividing) or which were too close together to reliably delineate 
individual cells were not used in the analysis. TMRM is a lipophilic 
cation that accumulates in the mitochondria according to the mitochon- 
drial membrane potential. TMRM fluorescence was analyzed using our 
own TMRM analysis script for the Fiji distribution of ImageJ. This tool 
uses a thresholding operation (Otsu) to designate all pixels as being ei- 
ther mitochondrial or background [32] . The average pixel intensity is 
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then calculated for both mitochondria and background, and the aver- 
age background intensity is subtracted from the average mitochondrial 
intensity for each image. 
Quantitative analysis of mitochondrial network morphology 
Mitochondrial network morphology was assessed using the Mito- 
chondrial Network Analysis Tool (MiNA) for the Fiji distribution of Im- 
ageJ [33] . Several pre-processing tools were used to enhance contrast 
and sharpen mitochondrial images, to ensure quantification by MiNA 
that closely represents the true fluorescence image. Differences in mi- 
tochondrial network abundance and complexity may require different 
image pre-processing to ensure that MiNA detection is accurate. For 
RASMC images, an unsharp mask (sigma = 1) was used to sharpen edges 
by subtracting a blurred version of the image (unsharp mask) from the 
image. To create the unsharp mask, the original image undergoes Gaus- 
sian blurring which is then multiplied by the mask weight (0.8). Second, 
a median filter (radius = 1) was applied to enhance contrast by replacing 
each pixel with the neighbourhood median. For RAENDO images, an un- 
sharp mask (sigma = 3) and a mask weight (0.9) were used followed by a 
median filter (radius = 1). Briefly, images underwent thresholding using 
the Otsu thresholding operation to produce a binary image [32] . Mito- 
chondrial footprint was calculated from the total area of mitochondrial- 
signal positive pixels. Mitochondrial form interconnected, branching 
networks in which branches are connected at a node. Following bina- 
rization, a morphological skeleton was then produced using the Skele- 
tonize 2D/3D plug-in [ 34 , 35 ]. This method employs iterative thinning 
to create a skeleton of mitochondrial structures, one pixel wide. Length 
measurements are then deduced from the morphological skeleton using 
the Analyze Skeleton plug-in. Mean branch length is calculated as the 
average length of a mitochondrial structure between two nodes. Mean 
network size was calculated by computing the sum of all branch lengths 
within an independent network and dividing this by the total number 
of individual networks within a cell. 
Statistical analysis 
Data are presented as means ± standard deviation. A one-way anal- 
ysis of variance (ANOVA) with Tukey’s multiple comparisons post-hoc 
analyses were performed for each data set. P values ≤ 0.05 were consid- 
ered significant. All statistical analyses were performed using GraphPad 
Prism version 9.1.0 (San Diego, CA). 
Results 
5. μM Zn 2 + treatment targets primarily mitochondrial transcripts while 50 
μM induces primarily metal regulatory pathways 
In initial experiments we measured the effects of continuous ZnSO 4 
treatment for 7 days on the growth and viability of RAENDO and RASMC 
cells (Fig. S1). At concentrations up to 50 μM, ZnSO 4 did not affect either 
growth or viability. We elected to use 5 μM and 50 μM as representative 
sublethal low and high ZnSO 4 treatments. 
To evaluate the effect of long-term zinc supplementation on rat aor- 
tic endothelial and smooth muscle global gene expression, we treated 
cells with 0 (Control), 5 μM or 50 μM of ZnSO 4 for 7 days, following 
which RNA was extracted and subsequently sequenced by Novogene 
(Sacramento, CA). 5 μM ZnSO 4 treatment elicited differential expres- 
sion of 251 transcripts in endothelial cells and 317 in smooth muscle 
cells. 60 of these genes were differentially regulated in both endothe- 
lial and smooth muscle cells ( Fig. 1 ). GO term analysis using the DAVID 
tool indicated that these 60 genes were associated primarily with ATP 
biosynthetic processes and oxidative phosphorylation, suggesting a mi- 
tochondrial and/or metabolic response at this concentration ( Fig. 1 A,C). 
50 μM ZnSO 4 treatment elicited differential expression of 325 genes in 
endothelial cells and 368 genes in smooth muscle cells. Of these, 77 
genes were commonly differentially regulated in both endothelial and 
smooth muscle cells. GO term analyses indicated that these 77 genes 
were associated with several biological processes including mitochon- 
drial fusion/fission dynamics, histone acetylation, negative regulation 
of growth, nitric oxide signalling, post-translational modification (i.e. 
neddylation, ubiquitination) and cellular response to/detoxification of 
metal ions ( Fig. 1 B,C). 
GO term analyses were also performed on DEG lists comparing 5 μM 
and 50 μM treatments to the respective cell-type control. The DEG lists 
were reduced to genes which had a p -value < 0.005 in order to produce 
very concise GO term lists. GO term analyses of gene lists containing 
genes with a p -value of < 0.05 results in a very similar GO term enrich- 
ment profile with some terms being excluded when the p -value is re- 
duced to < 0.005 (data not shown). Several cell-type specific responses 
to chronic zinc treatment were observed ( Fig. 2 ). At 5 μM ZnSO 4 , ATP 
biosynthetic processes and oxidative phosphorylation are strongly af- 
fected biological processes in RAENDO cells, whereas in RASMC cells 
glycolytic process and gluconeogenesis are affected. At 50 μM, both cell 
types demonstrate a strong effect of zinc treatment on metal ion regula- 
tion and cellular response to metal ions as well as protein neddylation 
and negative regulation of growth. The most strongly affected cellular 
compartment at 5 μM ZnSO 4 in RAENDO cells was the nucleus, whereas 
in RASMC cells it was the cytosolic large ribosomal subunit. There are 
no enriched cellular compartment GO terms for RAENDO cells at 50 μM, 
but the mitochondrion and nucleolus are the most strongly affected in 
RASMC cells. At 5 μM, nucleotide binding is the most affected molecular 
function in RAENDO cells, whereas in RASMC cells various protein bind- 
ing molecular functions are affected. At 50 μM, protein binding activity 
is affected in both cell types, with various hydrolase activities targeted 
in RAENDO cells and metal ion binding activity in RASMC cells. No- 
tably, the most strongly affected molecular function for RASMC cells 
treated with 50 μM ZnSO 4 was zinc ion binding. 
Genes related to mitochondrial processes, including oxidative phos- 
phorylation (e.g., Ndufa1 and Atp5f1 ), protein import ( Timm17b ) and 
network dynamics ( Mff and Mfn2 ) were among the transcripts with the 
greatest differences in levels in response to ZnSO 4 ( Fig. 3 ). In addition, 
several metallothionein genes are up-regulated in response to zinc treat- 
ment with no concomitant differential regulation of zinc-specific trans- 
porter proteins (e.g., ZnT or ZIP). Notably, the complex 1 gene Ndufa1 
was up-regulated in RAENDO cells, but down-regulated in RASMC cells. 
Transcripts related to mitochondrial network dynamics also showed dif- 
ferent responses in the two cell types. Up-regulation of mitochondrial 
fission factor ( Mff) in RAENDO cells suggests increased mitochondrial 
network fission, whereas up-regulation of mitofusin-2 ( Mfn2 ) in RASMC 
cells suggests increased mitochondrial fusion. Together these data indi- 
cate that mitochondria are a major target of ZnSO 4 , and we therefore 
focused on analyses of mitochondrial form and function in cells exposed 
to ZnSO 4 continuously for 7 days. 
Chronic zinc treatment has no effect on RAENDO OCR or ECAR but 
stimulate RASMC OCR and ECAR at 50 μM 
To determine the effect of chronic zinc supplementation on cellular 
energy metabolism, a Seahorse Mito Stress Test was performed follow- 
ing 7 days of treatment. No significant changes in basal or maximal 
OCR were observed in RAENDO cells at either concentration of ZnSO 4 
( Fig. 4 a). Similarly, there were no effects on ATP-linked or proton leak- 
linked OCR in these cells, or on ECAR, suggesting that zinc supplemen- 
tation has little significant effect on the energy metabolism of RAENDO 
cells. 
In contrast, ZnSO 4 treatment had substantial effects on energy 
metabolism in RASMC cells. Dose-dependent increases in basal and max- 
imal OCR were observed concomitantly with dose-dependent increases 
in ECAR ( Fig. 4 B). 
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Fig. 1. Venn diagrams of differentially expressed genes (DEGs) in RAENDO and RASMC cells treated with (a) 5 μM ZnSO 4 or (b) 50 μM ZnSO 4 compared to control 
(0 μM). (c) GO terms (biological process) of DEGs associated with the overlapping regions of Venn diagrams. 
Chronic zinc treatment reduces mitochondrial membrane potential in a 
dose-dependent manner in both cell types but does not affect apparent 
mitochondrial abundance 
We qualitatively determined mitochondrial membrane potential us- 
ing TMRM, a positively charged fluorescent dye that accumulates in the 
mitochondrial matrix relative to the membrane potential ( Fig. 5 ). 
Interestingly, ZnSO 4 treatment induced declines in membrane po- 
tential in both cell types, despite the absence of metabolic effects in 
RAENDO cells ( Fig. 5 B). Mitochondrial footprint ( Fig. 5 C) is the area 
of the cell in the binarized TMRM image that is occupied by mitochon- 
dria. This is a proxy of mitochondrial abundance, where an increase or 
decrease may indicate mitochondrial biogenesis or mitophagy, respec- 
tively. Interestingly, there was no evidence that mitochondrial footprint 
was affected by ZnSO 4 treatment in either cell type. 
Chronic zinc treatment cell-type specifically affects network morphological 
parameters 
Mitochondria form dynamic, branching networks in which individ- 
ual mitochondrial structures can fuse with or divide from a larger mito- 
chondrial network. These processes are highly regulated and responsive 
to changes in activities of two of the gene products identified as be- 
ing differentially expressed in the RNA-seq experiment: Mff and Mfn2 . 
To evaluate mitochondrial morphology, we used our mitochondrial net- 
work analysis (MiNA) tool for the Fiji distribution of ImageJ. We mea- 
sured mean branch length and mean summed branch length. Mean 
branch length and mean summed branch length measure the average 
length of mitochondrial structures, and the average summed length of 
branches within a network respectively, allowing for quantitative assess- 
ment of the extent to which mitochondria are fused into larger struc- 
tures or fragmented into smaller structures. In RAENDO cells, a dose- 
dependent reduction in mean branch length ( Fig. 5 D) and mean summed 
branch length ( Fig. 5 E) was observed, consistent with greater mitochon- 
drial fragmentation. This result is in agreement with the dose-dependent 
reduction in mitochondrial membrane potential and increased expres- 
sion of Mff [ 36 , 37 ]. In RASMC cells, a dose-dependent increase in mean 
branch length and mean summed branch length, which suggests that 
chronic zinc treatment enhances mitochondrial fusion and/or inhibits 
mitochondrial fission. A dose-dependent reduction in mitochondrial 
membrane potential is also observed in RASMC cells, which in addi- 
tion to larger network structures, may indicate a mechanism of mito- 
chondrial complementation to optimize mitochondrial function during 
wide-spread mitochondrial dysfunction or enhanced energy demands 
[ 37 , 38 ]. These results are consistent with our RNA-seq data, where 
RASMC demonstrate an up-regulation of the mitochondrial fusion gene, 
mitofusin-2 ( Mfn2 ). 
Discussion 
Materials selected for use as stents are ideally biologically inert so 
as to not interfere with local or systemic biological function. However, 
materials used in the past have failed to prevent the development of 
neointimal hyperplasia when applied in an atherosclerotic artery, lead- 
ing to incorporation of drug-eluting coatings that slowly release drugs 
such as rapamycin to prevent the development of smooth muscle hyper- 
plasia [ 17 , 39 , 40 ]. Several studies have indicated that aortic zinc metal 
implants result in confluent endothelization along the neointima and 
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Fig. 2. GO term analysis of differentially expressed genes in (a) RAENDO and (b) RASMC cells treated with 5 μM or 50 μM ZnSO 4 compared to control (0 μM). DEG 
lists for this analysis were reduced to genes with the Benjamini adjusted p -value < 0.005. ∗ positive regulation of, † with glutamine as amido-N-donor, ‡ acting on ester 
bonds. 
Fig.3. Significantly differentially expressed genes in (a) RAENDO and (b) RASMC cells treated with 5 μM or 50 ZnSO 4 treatment compared to control (0 μM). The top 5 
most significant protein-coding DEGs were selected from each gene list, and compared within cell types. Ndufa1; NADH dehydrogenase (ubiquinone) 1 𝛼 subcomplex 1, 
Pcdp5-like; programmed cell death protein 5-like (ENSEMBL gene ID: ENSRNOG00000050827), Mff; mitochondrial fission factor, Mrpl53; mitochondrial ribosomal 
protein L53, Hprt1; hypoxanthine phosphoribosyltransferase 1, Lig1-like; DNA ligase 1-like (ENSEMBL gene ID: ENSRNOG00000047206), ttpa-like; tissue-type 
plasminogen activator like (ENSEMBL gene ID: ENSRNOG00000060898), Mt1; metallothionein 1, Exoc7; exocyst complex component 7, Atp5f1; ATP synthase H + 
transporting mitochondrial Fo complex subunit B1, Ebna1np2; EBNA1 binding protein 2, Faah; fatty acid amide hydrolase, rCG54286-like; LOC1003619 (ENSEMBL 
gene ID: ENSRNOG00000020628), Cetn3-like; centrin-3-like (ENSEMBL gene ID: ENSRNOG00000050877), Uncharacterized A; AABR07066510.1 (ENSEMBL gene 
ID: ENSRNOG00000049123), Slc29a2; solute carrier family 29 member 2, Timm17b; translocase of the inner membrane 17b, Sepw1; selenoprotein W1, Mfn2; 
mitofusin 2, Echs-like; enoyl-CoA hydratase mitochondrial-like (ENSEMBL gene ID: ENSRNOG00000047565), Mt1a; metallothionein 1A, Mt2a; metallothionein 
2A, Nfs1; NFS1 cysteine desulferase, Uncharacterized B; LOC100909555 (ENSEMBL gene ID: ENSRNOG00000047746), Polr2l-like; DNA-directed RNA polymerase 
II subunit RPB9-like, Gstm5; glutathionine S-transferase mu 5, Uncharacterized C; AABR07028989.1 (ENSEMBL gene ID: ENSRNOG00000050441, DGCR1-like; 
integral membrane protein DGCR2/IDD-like (ENSEMBL gene ID: ENSRNOG00000049965), B9D1-like; B9 domain containing protein 1-like (ENSEMBL gene ID: 
ENSRNOG00000002462), Nhp2; NHP2 ribonucleoprotein. 
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Fig.4. Basal and maximal oxygen consumption rates (OCR) and extracellular acidification rates (ECAR) of (a) RAENDO and (b) RASMC following 7 days of treatment 
with 0–50 μM ZnSO 4 . Basal oxygen consumption is subdivided into non-mitochondrial (Non-mitochondrial), proton leak oxygen consumption (Leak) and ATP-linked 
oxygen consumption (ATP-linked). Spare respiratory capacity (Spare Capacity) is indicated on the maximal OCR bar. ∗ p -value ≤ 0.05. n = 4–12. 
a decreasing gradient of smooth muscle cells near the implant surface 
[15–17] . These results suggest that zinc-based stents may function as a 
possible alternative to drug-eluting stents for the prevention of in-stent 
restenosis in vivo . 
Guillory et al. hypothesized that corrosion products released from 
zinc implants exerts suppressive effects on smooth muscle cells via 
caspase-mediated apoptosis [17] . While it is well established that zinc 
plays a role in the determination and progression of apoptosis, the 
associated mechanisms and pathways are varied, cell-specific, and 
poorly understood [41] . Zinc has been reported to induce apoptosis 
through various pathways in several cell-types while demonstrating 
anti-apoptotic effects in others [ 12 , 41–44 ]. Previous cell culture studies 
with aortic smooth muscle and endothelial cells have demonstrated a 
reduction in cell viability, proliferation and migration rate at concen- 
trations at or above 100 μM [ 6 , 10 ]. Consistent with this, we saw no 
adverse effect of 5–50 μM ZnSO 4 on either cell growth or viability over 
7 days, while 100 μM ZnSO 4 slowed growth modestly in both cell lines 
(Supplementary Fig. 1). In contrast, treatment of various cell-types with 
50–100 μM ZnSO 4 can enhance proliferative signalling and cell motility 
[ 45 , 46 ]. 
In most mammalian cells, intracellular zinc concentrations range 
from 100 to 500 μM, with the vast majority of zinc ions being tightly 
bound to proteins; thus the total ‘free’ zinc concentration is in the pi- 
comolar range [ 47 , 48 ]. In the cell, maintenance of zinc ion concentra- 
tions is essential to prevent interference with other metal ions. If concen- 
trations exceed their normal range they will begin to bind where they 
would not otherwise under physiological conditions [ 49 , 50 ]. Accord- 
ing to the Irving-Williams series in inorganic chemistry, zinc ions bind 
much more strongly to proteins than most other biologically relevant 
ions including iron, manganese, magnesium and calcium [ 50 , 51 ]. Con- 
sequently, zinc regulatory proteins have binding affinities which reflect 
these physiological ranges and zinc concentrations are strictly regulated 
under physiological conditions [ 48 , 52 ]. 
There are two main mechanisms by which zinc homeostasis is main- 
tained; zinc transporting proteins such as zinc-transporters (ZnTs) and 
Zrt-Irt-like proteins (ZIPs) and the zinc buffer-storage system [ 53 , 54 ]. 
Recent studies using fluorescent zinc reporters indicate that mitochon- 
dria, ER, and Golgi act as potential sites of zinc buffers and storage in the 
maintenance of zinc homeostasis [55] . As a consequence, cell-type spe- 
cific sensitivity to zinc supplementation may be partially determined by 
the size and activities of the aforementioned intracellular storage sites. 
Muscle cells characteristically have large amounts of mitochondria in or- 
der to adequately support the energetic demands of muscle contraction 
while endothelial cells tend to rely primarily on glycolysis in order to 
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Fig. 5. Effects of 7 days continuous treatment with ZnSO 4 on mitochondrial parameters in live TMRM-stained cells. (a) Live cell TMRM fluorescence images 
of RAENDO and RASMC cells treated with 0–50 μM ZnSO 4 . On Day 7, cells were incubated with 10 nM TMRM for 30 min and subsequently imaged at 630x 
magnification using a Zeiss Cell Observer SD spinning disk confocal microscope. Scale bars represent 10 μm. (b,c) Relative mitochondrial membrane potential and 
mitochondrial footprint of (b) RAENDO and (c) RASMC. Cells were seeded on Day 5 of treatment. On Day 7, media was replaced and 10 nM TMRM added. Relative 
fluorescence intensity was evaluated to determine relative mitochondrial membrane potential. Total area of mitochondrial signal positive pixels was evaluated to 
determine mitochondrial footprint. (d–e) Mitochondrial network morphology analysis (MiNA) results for (d) RAENDO and (e) RASMC cells. Mean branch length was 
defined as the average length of a mitochondrial structure between two nodes. Mean network size was calculated by computing the sum of all branch lengths within 
an independent network and dividing this by the total number of individual networks within a cell. For b-e, ∗ ∗ p -value ≤ 0.01, ∗ ∗ ∗ ∗ p - value ≤ 0.0001. n = 49–144. 7 
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Fig. 5. Continued 
promote angiogenesis in hypoxic environments [56–59] . Interestingly, 
our GO term analysis indicates differential gene expression related to 
primarily oxidative phosphorylation at 5 μM ZnSO 4 in RAENDO cells 
compared to differential gene expression related to glycolysis and glu- 
coneogenesis in RASMC cells. 
Our RNA-seq data indicates that both RAENDO and RASMC cells up- 
regulate metallothionein (MT) genes in response to chronic zinc treat- 
ment but do not differentially regulate various zinc transporting proteins 
such as ZnTs/ZIPs. While ZnTs and ZIPs regulate the efflux and influx 
into the cytosol, respectively, MTs bind zinc to facilitate storage, buffer- 
ing and transfer to other proteins [ 60 , 61 ]. Regulation of these proteins at 
the level of gene expression to maintain zinc homeostasis has been pre- 
viously demonstrated with human coronary artery endothelial (HCAEC) 
and pulmonary artery smooth muscle cells (HPASMC) [62] . Abdo et al. 
indicated downregulation of ZnT1, ZnT2 and MT1 following treatment 
with 25 μM ZnSO 4 for 2 h as well as up-regulation of ZIP2 and ZIP12 
following zinc depletion with pyrithione in both HCAEC and HPASMC 
[62] . However, such changes in expression of ZnTs/ZIPs may represent 
an acute response to zinc supplementation and adaptation over several 
days may alter this response. Enhanced MT expression may represent 
the primary means of maintaining intracellular zinc homeostasis under 
chronic treatment. Interestingly, MT expression plays an important role 
in collateral flow recovery and angiogenesis which may provide addi- 
tional benefits when stents are applied in diseased arteries [63] . 
Our data indicate that mitochondria are influenced by zinc supple- 
mentation in a cell-type specific manner. Mitochondrial form highly dy- 
namic networks which undergo cycles of fusion and fission in response 
to various cellular stimuli. We demonstrate that zinc treatment of en- 
dothelial cells results in a dose-dependent increase in mitochondrial 
fission, whereas smooth muscle cells demonstrate a dose-dependent in- 
crease in mitochondrial fusion. Mitochondrial fission is regulated by sev- 
eral key players, including dynamin related protein 1 (DRP1) and mito- 
chondrial fission factor (MFF) [36] . Consistent with morphology results, 
RNA-seq analyses showed an upregulation of Mff in endothelial cells at 
5 μM and 50 μM ZnSO 4 . Mitochondrial fission is often indicative of mi- 
tochondrial damage or dysfunction as it typically precedes mitophagy, 
the autophagic elimination of mitochondria. In fact, depolarization of 
the mitochondrial membrane potential (MMP) enhances mitophagy by 
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promoting ubiquitination of mitochondrial surface proteins and activa- 
tion of mitochondrial fission machinery [ 37 , 64 ]. MFF recruits active 
and oligomeric DRP1 to the mitochondrial outer membrane to promote 
fission. A recent study demonstrated that DRP1 interacts with the mito- 
chondrial zinc transporter, ZIP1 to focally reduce mitochondrial mem- 
brane potential by promoting zinc entry through the ZIP1-mitochondrial 
calcium uniporter (MCU) complex [65] . Following fission, dysfunctional 
mitochondria fail to recover membrane potential and are subsequently 
degraded by mitophagy [65] . Further, recent studies have determined 
that zinc entry into mitochondria through the MCU plays an important 
role in the development of mitochondrial dysfunction and promotion of 
cell death following ischemia [66] . Taken together, the relationship be- 
tween mitochondrial fission machinery, MMP and metal ionic balance is 
complex and poorly understood but may play a role in the development 
of stably reduced MMP in cells treated with ZnSO 4 over 7 days. 
In smooth muscle cells, Mfn2 is upregulated at 5 μM but not 50 μM, 
despite a dose-dependent increase in network morphological parame- 
ters indicative of fusion. MFN2 is a dynamin-like GTPase important for 
mitochondrial fusion, calcium homeostasis, and ER-mitochondrial con- 
tact [67] . Several studies have shown that MFN2 inhibits cell prolifer- 
ation and cell-cycle progression in several cell-types. In fact, the MFN2 
gene was originally implicated for its role in the suppression of vascu- 
lar proliferative disorders such as smooth muscle hyperplasia [67–69] . 
Therefore, upregulation of this gene and/or activation of the MFN2 pro- 
tein in the presence of zinc may slow cell-cycle progression and prevent 
restenosis in vivo . MFN2 is also important for establishing mitochondrial- 
ER contact sites [70] . Functional ER-mitochondrial coupling promotes 
efficient calcium uptake into mitochondria, resulting in higher mito- 
chondrial membrane potential, oxygen consumption and ATP produc- 
tion [70–72] . During vascular injury, such as following angioplasty, vas- 
cular smooth muscle cells can undergo a phenotypic switch from a ma- 
ture ‘contractile’ phenotype to a de-differentiated, highly proliferative 
and secretory phenotype, leading to the development of neointimal hy- 
perplasia [73–77] . In addition, dysregulation of mitochondrial dynamics 
and/or mitochondrial-ER coupling can promote the secretory and pro- 
liferative phenotype of vascular smooth muscle cells [ 70 , 71 , 78 ]. There- 
fore, up-regulation of Mfn2 during chronic zinc supplementation may 
promote mitochondrial-ER contact and mitochondrial calcium home- 
ostasis, thus preventing hyperplasia and restenosis in vivo . It is unclear 
why Mfn 2 is upregulated at 5 μM but not 50 μM ZnSO 4 , despite con- 
sistent enhanced mitochondrial fusion at this concentration. Mitochon- 
drial fusion may also occur during periods of stress or increased ATP 
demand, as a means of maximizing mitochondrial function by mixing 
partially damaged components as a form of complementation [ 37 , 38 ]. 
Mitochondrial quality control can be maintained through the elimina- 
tion of damaged proteins by proteases and refolding by chaperone pro- 
teins in the mitochondrial matrix [ 37 , 79 , 80 ]. Outer membrane proteins 
can be removed through the ubiquitin-proteosome pathway [ 37 , 81 ]. 
Our GO term analyses of differential gene expression indicate positive 
regulation of ubiquitin transferase activity and ubiquitin-related protein 
binding in both cell types. This may indicate an alternative mechanism 
for mitochondrial quality control during chronic zinc supplementation. 
Several of our data suggest that treatment of smooth muscle cells 
with zinc leads to an increase in ATP demand. Enhanced basal and maxi- 
mal oxygen consumption rates as well as extracellular acidification rates 
suggest that both mitochondrial and glycolytic ATP-producing reactions 
are working at faster rates. GO term analyses indicating differential reg- 
ulation of genes associated with glycolysis and gluconeogenesis further 
indicate increased ATP demand. While previous studies have suggested 
that zinc acts as an inhibitor of cellular energy production both within 
the electron transport system and glycolysis, most of these studies were 
performed in cell-free systems in the absence of the cell’s endogenous 
zinc-buffering capacity [82–86] . Increases in ATP demand may be rel- 
evant to increases in intracellular zinc concentrations, where zinc ions 
can disrupt binding of other essential metal ions such as magnesium. 
Magnesium homeostasis is essential for regulation of tricyclic acid cy- 
cle (TCA) enzymatic activity and maintenance of the electron transport 
system [87–90] . Moreover, ATP binds to the magnesium ion to form 
the biologically functional form Mg-ATP. Mitochondrial ATP is trans- 
ported from the mitochondria in the magnesium bound form by the 
ATP-Mg/Pi [ 87 , 91–93 ] Magnesium is also an essential co-factor for the 
sodium/potassium pump, a major cellular ATP consumer required for 
maintenance of the cellular membrane potential [ 93 , 94 ]. Thus, disrup- 
tion of magnesium or other essential metal ion binding by zinc may 
contribute to dysregulation of metabolism and enhanced ATP demand. 
Mitochondrial dysfunction or damage may also enhance ATP de- 
mand. During mitochondrial dysfunction, ATP synthase may consume 
ATP in order to generate and maintain mitochondrial membrane po- 
tential [ 37 , 95 ]. Our data provides significant evidence for disruption of 
the mitochondrial membrane potential, including dose-dependent de- 
polarization of the inner membrane and up-regulation of the translo- 
case of the inner membrane subunit 17b ( Timm17b ) in RASMC cells. 
TIMM17B is an essential component of the TIM23 complex required 
for protein import into the mitochondrial matrix [96] . Previous stud- 
ies have indicated that mitochondrial stress induces the expression of 
mitochondrial import machinery in order to efficiently import proteins 
required for the mitochondrial unfolded protein response during peri- 
ods of reduced mitochondrial membrane potential [80] . Therefore, up- 
regulation of Timm17b may indicate a mechanism to ensure mitochon- 
drial quality control and function during chronic zinc supplementation. 
Conclusions 
In summary, the differential effects of zinc on rat vascular endothe- 
lial and smooth muscle cells observed in vivo [15–17] are concomitant 
with differential effects on mitochondria and energy metabolism in vitro . 
We observed cell-type specific changes in gene expression related to 
several mitochondrial genes as well as corresponding changes in mito- 
chondrial form and function. These differences may arise from cell-type 
specific differences in zinc-buffer and storage capacity requiring differ- 
ent mechanisms for the maintenance of mitochondrial quality control 
and function with chronic zinc supplementation. This study examines 
the effect of zinc supplementation over 7 days in order to represent the 
long-term effects of zinc exposure during stent application in vivo . The 
identification of mitochondria as an important target of zinc that is dif- 
ferently affected in the vascular endothelial and smooth muscle cells is 
important for better understanding how zinc-based implants affect tis- 
sue homeostasis in vivo . 
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